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Timing of antiretroviral therapy and TB treatment outcomes  
in patients with TB-HIV in Myanmar
A. M. Thi,1 H. D. Shewade,2 N. T. T. Kyaw,1 M. M. Oo,1 T. K. Aung,1 S. T. Aung,3 H. N. Oo,4 T. Win,5  
A. D. Harries6,7
The success of tuberculosis (TB) control is threat-ened by the increase in human immunodefi-
ciency virus (HIV) associated TB. In 2014, 9.6 million 
patients globally were estimated to have developed 
TB, of whom 1.2 million (12%) were co-infected with 
HIV. Of these, 390 000 (33%) died while undergoing 
anti-tuberculosis treatment (ATT).1 This mortality rate 
is high considering that TB can be successfully cured 
with standard ATT regimens and HIV can be success-
fully managed with long-term antiretroviral therapy 
(ART). In 2012, the World Health Organization 
(WHO) published a policy document on collaborative 
TB-HIV activities to reduce the burden of dual disease 
that focused on 1) mechanisms for delivering inte-
grated TB and HIV services, 2) early ART and the 
‘Three I’s’ (intensified case finding, isoniazid preven-
tive therapy and TB infection control for people liv-
ing with HIV) to reduce the burden of TB in people 
living with HIV, and 3) activities to reduce the burden 
of HIV in patients with presumptive and diagnosed 
TB.2
Myanmar ranks seventeenth among the 22 high TB 
burden countries, and has one of the most severe HIV/
AIDS (acquired immune-deficiency syndrome) epi-
demics in Asia, with a prevalence of 0.53% in adults.1,3 
As a result of this dual epidemic, there is likely to be a 
significant burden of HIV-associated TB. In 2013, ac-
cording to the WHO report, only 16 882 (12%) of the 
notified TB patients in the country were HIV tested; 
5413 were found to be HIV-positive, of whom 4006 
(74%) were recorded as being on ART during ATT.3 For 
the 2011 TB cohort, only 65% of HIV-infected TB pa-
tients successfully completed treatment, which was 
much lower than the rate of 89% amongst newly diag-
nosed TB patients overall. These data suggest that 1) 
there is a significant pool of patients with TB-HIV who 
are not diagnosed or offered HIV care, and 2) for those 
who are diagnosed and treated, outcomes are poor.
Amongst the TB-HIV patient cohort in the Inte-
grated HIV Care (IHC) programme in Mandalay, one 
group of adults was initiated on ART after starting ATT 
(ATT-first group) and the second group was initiated 
on ATT after ART (ART-first group). This provides an 
opportunity to assess TB treatment outcomes in both 
groups. In the ATT-first group, it is now well estab-
lished that an earlier start of ART after ATT com-
mencement, especially in those with low CD4 cell 
counts, is associated with reduced TB case fatality.4–6 
In Myanmar, there is no published national informa-
tion about when patients with TB-HIV start ART or 
whether this affects TB treatment outcomes. This 
study was therefore planned in the IHC programme, 
Mandalay, Myanmar, between 2011 and 2014 with 
the following objectives: to determine among patients 
with TB-HIV 1) the time to start ART and the relation-
ship to TB treatment outcomes in the ATT-first group; 
and 2) the time spent on ART before ATT and the rela-
tionship to TB treatment outcomes in the ART-first 
group.
METHODS
Study design
This was a retrospective cohort study involving record 
review.
Setting
General setting
Myanmar, situated in South-East Asia, has an esti-
mated population of 53 million, of whom 60% live in 
Received 17 January 2016
Accepted 25 February 2016
http://dx.doi.org/10.5588/pha.16.0009
Setting: Integrated HIV Care programme, Mandalay, 
Myanmar.
Objectives: To determine time to starting antiretroviral 
treatment (ART) in relation to anti-tuberculosis treatment 
(ATT) and its association with TB treatment outcomes in 
patients co-infected with tuberculosis (TB) and the hu-
man immunodeficiency virus (HIV) enrolled from 2011 to 
2014.
Design: Retrospective cohort study.
Results: Of 1708 TB-HIV patients, 1565 (92%) started 
ATT first and 143 (8%) started ART first. Treatment out-
comes were missing for 226 patients and were thus not 
included. In those starting ATT first, the median time to 
starting ART was 8.6 weeks. ART was initiated after 8 
weeks in 830 (53%) patients. Unsuccessful outcome was 
found in 7%, with anaemia being an independent pre-
dictor. In patients starting ART first, the median time to 
starting ATT was 21.6 weeks. ATT was initiated within 3 
months in 56 (39%) patients. Unsuccessful outcome was 
found in 12%, and in 20% of those starting ATT within 3 
months. Patients with CD4 count 100/mm3 had a four 
times higher risk of an unsuccessful outcome.
Conclusions: Timing of ART in relation to ATT was not 
an independent risk factor for unsuccessful outcome. Ex-
tensive screening for TB with rapid and sensitive diagnos-
tic tests in HIV-infected persons and close monitoring of 
anaemia and immunosuppression are recommended to 
further improve TB treatment outcomes among patients 
with TB-HIV.
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rural areas. The National Tuberculosis Programme 
(NTP), together with partners, offers diagnostics, cost-
free treatment and follow-up services for patients with 
presumptive and confirmed TB, based on the WHO TB 
treatment guidelines.7 The National AIDS Programme 
(NAP), together with partners, offers HIV testing and 
counselling, and for HIV-positive patients, care and 
ART.8 TB-HIV collaborative activities in Myanmar were 
launched in collaboration with the International 
Union Against Tuberculosis and Lung Disease (The 
Union) in Mandalay in seven townships in 2005. After 
scaling up decentralisation of HIV counselling and 
testing, TB-HIV sites had expanded to 236 townships 
by 2015.
Integrated HIV Care programme and study site
The Union implements the IHC programme in the 
public sector in 24 townships through 34 service deliv-
ery clinics in Myanmar in collaboration with the NTP, 
the NAP and the Ministry of Health (MOH). The de-
tails of the IHC programme and the ART and ATT regi-
mens used have been described previously.9 Briefly, the 
first-line ART regimen up to 2012 was zidovudine or 
stavudine with lamivudine and nevirapine or efa-
virenz; since 2012 it has consisted of tenofovir, lami-
vudine and efavirenz. The second-line regimen is pro-
tease inhibitor based. ATT regimens follow WHO 
guidelines.7 For the sake of infection control, all TB-
HIV patients are enrolled in one particular clinic in the 
Mandalay IHC programme. All TB-HIV patients are ini-
tiated on ART and cotrimoxazole preventive therapy 
(free of charge) in line with the NAP guidelines, based 
on the WHO 2010 guidelines.8,10
Along with the necessary laboratory investigations, 
all patients on ART are carefully monitored at the clin-
ics by clinicians, and are seen every 3 months if 
healthy and more frequently if sick. The data for pa-
tients initiating ART and followed up on treatment are 
entered in patient files that are kept securely in lock-
able cabinets. Every week these data are single-entered 
into a central electronic database at the office head-
quarters in Mandalay. 
Patient population
All patients with TB-HIV (aged 15 years) enrolled in 
the Mandalay IHC programme and initiated on ART 
between 2011 and 2014 were included in the study. 
Drug-resistant TB cases were excluded from the study.
Data variables, sources of data and data 
collection
The source of data was the Mandalay central elec-
tronic database, and data were extracted between 
March and November 2015. Data variables included 
the IHC registration number; the start date of ATT; 
the start date of ART; the age at the time of ATT initi-
ation; sex; CD4 cell count and body mass index (BMI) 
before or after 6 months of ATT initiation; haemoglo-
bin, hepatitis B and hepatitis C status at the time of 
registration at the IHC clinic; the category and site of 
TB; and TB treatment outcomes. The classification of 
anaemia and BMI (for Asian populations) were per 
WHO recommendations.11,12
Analysis and statistics
Data were extracted into Excel (Microsoft Corp, Red-
mond, WA, USA) and imported into EpiData analysis 
software version 2.2.2.183 (EpiData Association, 
Odense, Denmark). Univariate analysis and adjust-
ment for single confounders was performed using Epi-
Data analysis software. Multivariate analysis was per-
formed using STATA version 12.1 (STATA Corp, College 
Station, TX, USA).
Analyses were performed in relation to the two 
groups of TB-HIV patients: ATT first and ART first. 
Within each group, frequency and proportions were 
used to summarise baseline characteristics and ATT 
outcomes. The median interquartile range (IQR) was 
used to summarise the time between ATT and ART. As-
sociations between ATT outcomes and time between 
ART and ATT (including baseline characteristics) were 
summarised using relative risks (adjusted for con-
founding wherever applicable using the Mantel 
Haenszel method) and 95% confidence intervals (CI). 
Among those who started ATT first, log binomial re-
gression (enter method) was used and variables with 
univariate P  0.2 were included in the model. Among 
those who started ART first, we did not perform log bi-
nomial regression because a high number of records 
(30%) had missing data in at least one of the explana-
tory variables.
Ethics approval
Permission for the study was obtained from the Myan-
mar NAP and NTP. Ethics approval was obtained from 
the Ethics Advisory Group, The Union, Paris, France. 
As this study involved the analysis of secondary pro-
grammatic data, the need for informed patient con-
sent was waived.
RESULTS
Between 2011 and 2014, 1934 patients with TB-HIV 
were enrolled on treatment. Of these, 226 (12%) had 
no treatment outcomes recorded, and 1708 patients 
with TB-HIV were included in the study. The baseline 
characteristics of the study participants are sum-
marised in Table 1. At the time of ATT initiation, 776 
(45%) had a baseline CD4 100/mm3 and 1013 (59%) 
were underweight. At the time of entry into IHC care, 
1305 (76%) patients had anaemia, 156 (9%) were sero-
positive for hepatitis B and 164 (10%) were seroposi-
tive for hepatitis C.
The timing of ART in relation to ATT and the ATT 
outcomes are shown in Table 2. Of all patients with 
TB-HIV (n = 1708), 1565 (92%) started ATT first and 
143 (8%) started ART first.
‘ATT-first’ group
Among those patients who started ATT first, ART was 
initiated within 8 weeks of starting treatment in 735 
(47%) patients and after 8 weeks in 830 (53%) patients 
(Table 2). The median (IQR) time in weeks to initiation 
of ART was 8.6 (5.7–13.7). Seven per cent of the pa-
tients had an unsuccessful outcome (Table 2). After ad-
justing for various confounders, patients with non-se-
vere anaemia had a 3.5 times higher risk of an 
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unsuccessful outcome, while those with severe anaemia had a 6 
times higher risk, compared with patients with no anaemia. The 
timing of ART initiation (early or late) was not significantly asso-
ciated with unsuccessful outcomes (Table 3).
‘ART-first’ group
Among those patients who started ART first, ATT was initiated 
within 3 months of initiating ART in 56 (39%) patients, while 87 
(61%) started ATT after 3 months (Table 2). The median (IQR) 
time in weeks to starting ATT was 21.6 (6.0–60.7). An unsuccess-
ful outcome was recorded for 12% of the patients (Table 2) and 
for 19.6% of a subset of patients who started ATT within 3 
months of starting ART (data not shown). After adjusting for ATT 
initiation, patients with a CD4 count 100/mm3 had a more than 
four-fold higher risk of an unsuccessful outcome compared to pa-
tients with a CD4 count 100/mm3. Patients who were started on 
ATT within 3 months had a three-fold higher risk of an unsuc-
cessful treatment outcome compared with those who started ATT 
after 3 months. However, this association appeared to be con-
founded by CD4 count (Table 4).
DISCUSSION
This is the first study from Myanmar to evaluate the timing of ART 
and associated ATT outcomes in a large TB-HIV cohort over 3 
years. The overall proportion of patients with an unsuccessful 
treatment outcome was small. In those starting ART first, the risk 
of an unsuccessful outcome was higher in patients with a low CD4 
count and in those who commenced on ATT within the first 3 
months, although the timing of ATT was not an independent risk 
factor. In patients starting ATT first, anaemia appeared to be the 
most significant factor associated with an unsuccessful outcome.
The strengths of this study are a robust methodology, which 
included pre-defined operational definitions for the study popula-
tion and variables, a large sample, adjusted measures of associa-
tion and adherence to the Strengthening The Reporting of OBser-
vational studies in Epidemiology (STROBE) guidelines for 
conducting and reporting on observational studies.13 As we stud-
ied the entire population of patients with TB-HIV initiated on ART 
between 2011 and 2014 at the study site, the results are likely to 
be representative for the region. However, there were some limita-
tions. Data on TB treatment outcomes were missing for more than 
TABLE 1 Baseline characteristics of all patients with TB-HIV initiated 
on ART at the IHC programme, Mandalay, Myanmar, 2011–2014
Variable
All patients
with TB-HIV
n (%)
Started ATT 
first
n (%)
Started ART 
first
n (%)
Total 1708 (100) 1565 (100) 143 (100)
Age, years*
 15–34 693 (41) 627 (40) 66 (46)
 35–54 958 (56) 884 (57) 74 (52)
 55–75 57 (3) 54 (4) 3 (2)
Sex
 Male 1223 (72) 1139 (73) 84 (59)
 Female 485(28) 426 (27) 59 (41)
TB site
 EPTB 661 (39) 596 (38) 65 (46)
 PTB 1045(61) 968 (62) 77 (54)
 Missing 2 (0) 1 (0) 1 (1)
TB category
 New 1495 (88) 1415 (90) 81 (56)
 Retreatment 146 (9) 110 (7) 36 (25)
 Other 5 (0) 3  (0) 2 (1)
 Missing 62 (4) 37 (2) 25 (18)
CD4 count, cells/mm3†
 CD4 100 776 (45) 727 (47) 49 (34)
 CD4 100 922 (54) 829(53) 93 (65)
 Missing 10 (1) 9 (1) 1 (1)
Baseline BMI, kg/m2†
 Underweight (18.5) 1013 (59) 926 (60) 87 (61)
 Normal (18.5–22.9) 479 (28) 438 (28) 41 (29)
 Overweight (23–27.5) 88 (5) 83 (5) 5 (4)
 Obese (27.5) 18 (1) 17 (1) 1 (1)
 Missing 110 (6) 101 (7) 9 (6)
Anaemia‡
 None 351 (21) 325 (21) 26 (18)
 Anaemia, not severe 1129 (66) 1059 (68) 70 (49)
 Anaemia, severe 176 (10) 159 (10) 17 (12)
 Missing 52 (3) 22 (1) 30 (21)
Hepatitis B‡
 Yes 156 (9) 141 (9) 15 (11)
 No 1426 (84) 1309 (84) 117 (82)
 Not recorded 126 (7) 115 (7) 11 (8)
Hepatitis C‡
 Yes 164  (10) 151 (10) 13 (9)
 No 1418 (83) 1300 (83) 118 (83)
 Not recorded 126 (7) 114 (7) 12 (8)
* Age at the time of ATT initiation.
† CD4 and BMI before or 6 months after ATT initiation.
‡ Anaemia, hepatitis B and hepatitis C data at the time of registration at the IHC 
clinic.
TB = tuberculosis; HIV = human immunodeficiency virus; ART = antiretroviral ther-
apy; IHC = Integrated HIV Care; ATT = anti-tuberculosis treatment; EPTB = extra-pul-
monary TB; PTB = pulmonary TB; BMI = body mass index.
TABLE 2 ART initiation and ATT outcomes of all patients with 
TB-HIV initiated on ART in the IHC programme, Mandalay, Myanmar, 
2011–2014
Variable
All patients 
with TB-HIV
n (%)
Started  
ATT first
n (%)
Started  
ART first
n (%)
Total 1708 (100) 1565 (100) 143 (100)
ART initiation
 ATT first
  ART within 8 weeks 735 (43) 735 (47) —
  ART after 8 weeks 830 (49) 830 (53) —
 ART first
  ATT within 3 months 56 (3) — 56 (39)
  ATT after 3 months 87 (5) — 87 (61)
TB outcome
 Cured 32 (2) 27 (2) 5 (4)
 Completed 1555 (91) 1434 (92) 121 (85)
 Treatment failure 6 (0) 5 (0) 1 (1)
 Death 107 (6) 91 (6) 16 (11)
 Loss to follow-up 8 (1) 8 (1) —
TB final outcome* 
 Successful 1587 (93) 1461 (93) 126 (88)
 Unsuccessful 121 (7) 104 (7) 17 (12)
* Successful outcome includes cured and completed; unsuccessful outcome includes 
treatment failure, death or loss to follow-up.
ART = antiretroviral therapy; ATT = anti-tuberculosis treatment; TB = tuberculosis; 
HIV = human immunodeficiency virus; IHC = Integrated HIV Care.
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10% of the patients. There was a high proportion of missing data 
for TB treatment outcome dates, which precluded a time to event 
analysis. As data on the ART regimen at the time of ATT initiation 
were not readily available, we could not determine the effect of 
ART regimens on treatment outcomes. Data on haemoglobin were 
recorded on entry to the IHC clinic and not during ATT initiation.
There were some important findings in this study. First, base-
line anaemia at entry to the IHC clinic was common and an inde-
pendent risk factor for unsuccessful ATT outcomes in those start-
ing ATT first. Moderate to severe anaemia at entry into HIV care 
increases the risk for TB among HIV-infected patients.14 Previous 
studies have also documented a high prevalence of anaemia in 
patients with TB-HIV, associated with delayed sputum conversion, 
poor immune recovery and increased mortality.15–19
Second, the timing of ART in relation to ATT was not an inde-
pendent risk factor for unsuccessful outcomes. It is well known 
that ART before or after ATT is associated with decreased TB mor-
tality.20,21 Early initiation of ART within 8 weeks of ATT or within 
2–4 weeks is associated with a lower risk of mortality, especially 
among those with low CD4 cell counts, even though there is a 
higher risk of immune reconstitution inflammatory syn-
drome.4,22–25 This evidence endorses the current WHO recommen-
dations that ART be used for all individuals with TB, regardless of 
their CD4 count, as soon as possible within the first 8 weeks of 
ATT and as early as within 2 weeks if the CD4 count is 50 cells/
mm3.26 However, the evidence for these effects is not consistent 
with some studies that show no significant differences in survival 
between early and late initiation of ART.27,28 The findings from 
our study, in which nearly half the patients had a CD4 count 
100 cells/mm3, are in line with these observations. It is likely 
that in the routine setting other patient factors, such as access to 
the clinic, financial security, clinical condition and patient readi-
ness, play a part in determining treatment outcomes.
Third, in the ART-first group, around 40% started ATT within 3 
months. This suggests that TB might have been prevalent at the 
time of starting ART, with the disease being missed at the initial 
screening because of the difficulties in establishing a diagnosis of 
TB in the context of severe immunosuppression or the disease be-
ing subclinical and becoming unmasked during immune reconsti-
tution. ART failure may also have been a reason for TB developing 
after 3 months of ART initiation. It is well known that patients 
who develop TB soon after starting ART are at higher risk of 
mortality.29
Our study concurs with these observations, although the asso-
ciation was confounded by severe immunosuppression. These 
findings do, however, suggest that better, more sensitive tests are 
required to diagnose TB in severely immune-suppressed patients. 
Rapid, sensitive tests such as Xpert® MTB/RIF (Cepheid, Sunny-
vale, CA, USA) and/or urine TB lipoarabinomannan (LAM) have 
been found to be useful in detecting prevalent TB among HIV pa-
TABLE 3 Risk factors associated with unsuccessful ATT outcomes among patients with TB-HIV who 
initiated ATT first in the IHC programme, Mandalay, Myanmar, 2011–2014
Variable
Total  
assessed*
n
Unsuccessful 
outcomes
n (%)
RR
(95%CI)
Adjusted RR†
(95%CI)
Total 1565 104 (7)
Age, years‡ 1565
 15–34 627 47 (7.5) 1.3 (0.9–1.8) 1.4 (0.9–2.3) 
 35–54 884 53 (6.0) 1 (Ref) 1 (Ref)
 55–75 54 4 (7.4) 1.2 (0.5–3.3) 1.1 (0.3–4.7)
Sex 1565
 Female 426 26 (6.1) 0.9 (0.6–1.4) 0.8 (0.5–1.4)
 Male 1139 78 (6.8) 1 (Ref) 1 (Ref)
CD4 count, cells/mm3§ 1556
  100 727 58 (8.0) 1.7 (1.1–2.4) 1.3 (0.8–2.1)
 100 829 40 (8.8) 1 (Ref) 1 (Ref)
Baseline BMI§ 1464
 Underweight 926 55 (5.9) 1.7 (0.9–3.0) 1.4 (0.8–2.5)
 Normal 438 15 (3.4) 1 (Ref) 1 (Ref)
 Overweight 83 0 0 (inf–inf) —
 Obese 17 1 (5.9) 1.7 (0.2–12.3) 1.7 (0.2–12.2)
Anaemia¶ 1543
 None 325 6 (1.8) 1 (Ref) 1 (Ref)
 Anaemia, not severe 1059 70 (7.5) 3.9 (1.7–9.0) 3.5 (1.3–9.6)#
 Anaemia, severe 159 19 (11.9) 6.5 (2.6–15.9) 6.1 (2.0–18.3)#
ART initiation 1565
 Within 8 weeks 735 58 (7.9) 1 (Ref) 1 (Ref)
 After 8 weeks 830 46 (5.5) 0.7 (0.5–1.0) 1.0 (0.6–1.5)
* Records with missing explanatory variables removed from analysis.
† Variables with univariate P  0.2 were included in the log binomial regression model (enter method).
‡ Age at the time of ATT initiation.
§ Before or 6 months after ATT initiation.
¶ At the time of registration at the IHC clinic.
# Statistically significant, P  0.05.
ATT = anti-tuberculosis treatment; TB = tuberculosis; HIV = human immunodeficiency virus; BMI = body mass index; IHC = Inte-
grated HIV Care; RR = relative risk; CI = confidence interval; ART = antiretroviral therapy.
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tients with advanced disease, and these should be considered as 
part of the diagnostic package in these patients.14,15 The Mandalay 
IHC, in collaboration with the NTP, started initiating Xpert testing 
for HIV patients in 2013. This is a step in the right direction.
There are some important policy recommendations from this 
study. First, routine data collection must be improved so that all 
variables that should be collected are actually collected. Second, 
routine measurement of haemoglobin in patients with TB-HIV 
would be useful, with moderate/severe anaemia being used to 
identify those at risk for TB among HIV-infected patients and 
those at risk of poor outcomes among TB-HIV patients, who 
might need closer and more frequent clinical monitoring. Third, 
the IHC programme should strongly consider the scale-up of 
Xpert testing for HIV patients and the deployment and use of 
urine LAM to diagnose TB much earlier than is probably the case. 
Finally, there is scope to get more patients initiated on early ART. 
The rapid advice issued by the WHO in September 2015 recom-
mended that all persons with HIV start ART, regardless of CD4 
cell count and WHO clinical stage.30 There is strong evidence that 
this approach reduces mortality and risk of TB,31,32 and this would 
help to reduce TB incidence and TB mortality in patients living 
with HIV. In this regard, there is also good evidence that the addi-
tion of isoniazid preventive therapy to ART can further reduce the 
risk of TB and other adverse outcomes,32,33 and should be consid-
ered as part of the package.
In conclusion, the study found generally good treatment out-
comes in patients with TB-HIV enrolled for care in the IHC pro-
gramme in Mandalay, Myanmar. Although unsuccessful outcomes 
were more common in patients starting ART before ATT, the tim-
ing of ART in relation to ATT was not an independent risk factor. 
The issues identified in this study need to be addressed for the 
programme to achieve the target of ending the epidemic of TB 
and HIV by 2030 in line with the recently released Sustainable 
Development Goals.34
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TABLE 4 Risk factors associated with unsuccessful ATT outcomes among patients with TB-HIV who 
initiated ART first at the IHC Programme, Mandalay, Myanmar, 2011–2014
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Contexte  :  Programme intégré de prise en charge du virus de 
l’immunodéficience humaine (VIH), Mandalay, Myanmar.
Objectifs  :  Chez les patients atteints de tuberculose (TB) et VIH 
enrôlés entre 2011 et 2014, déterminer la date du début du 
traitement antirétroviral (TAR) en relation avec le traitement 
antituberculeux (ATT) et son association avec le résultat d’ATT.
Schéma  :  Etude rétrospective de cohorte.
Résultats  :  Sur 1708 patients TB-VIH, 1565 (92%) ont débuté l’ATT 
en premier et 143 (8%) ont commencé le TAR en premier. Le résultat 
du traitement a été manquant pour 226 patients qui n’ont pas été 
inclus. Chez les patients ayant débuté l’ATT en premier, le délai 
médian de mise en route du TAR a été de 8,6 semaines. L’initiation 
du TAR a été retardée d’un délai médian de 8 semaines chez 830 
(53%) patients. Parmi ces patients, 7% ont eu un résultat médiocre, 
avec une anémie qui a constitué un facteur de risque indépendant. 
Chez les patients ayant débuté le TAR en premier, le délai médian de 
mise en route de l’ATT a été de 21,6 semaines. L’ATT a été initié au 
cours des 3 mois chez 56 (39%) patients. Le traitement a échoué 
chez 12% des patients et chez 20% de ceux qui ont débuté l’ATT 
dans les 3 mois. Les patients ayant des CD4 100/mm3 ont eu un 
risque quatre fois plus élevé d’échec.
Conclusions  :  La chronologie du TAR en rapport avec l’ATT n’a pas 
été un facteur de risque indépendant d’échec du traitement. Un 
dépistage extensif de la TB avec des tests de diagnostic rapides et 
sensibles chez les personnes infectées par le VIH et un suivi étroit de 
l’anémie et de l’immunosuppression sont recommandés afin 
d’améliorer encore le résultat du traitement de TB parmi les patients 
TB-VIH.
Marco de referencia: El programa integrado de atención de la 
infección por el virus de la inmunodeficiencia humana (VIH) en 
Mandalay, en Birmania.
Objetivos: Determinar el lapso entre el comienzo del tratamiento 
antirretrovírico (ART) y el inicio del tratamiento antituberculoso (ATT) 
en los pacientes coinfectados registrados del 2011 al 2014 y su 
asociación con el desenlace del ATT.
Método: Fue este un estudio retrospectivo de cohortes.
Resultados: De los 1708 pacientes coinfectados por el VIH y la 
tuberculosis (TB), 1565 iniciaron primero el ATT (92%) y 143 
comenzaron en primer lugar el ART (8%). Se excluyeron 226 casos 
que carecían de registro del desenlace terapéutico. En los pacientes 
que iniciaron en primer lugar el ATT, la mediana del lapso hasta el 
comienzo del ART fue 8,6 semanas; este tratamiento se inició después 
de 8 semanas en 830 pacientes (53%). Se observó un desenlace 
terapéutico desfavorable en 7% de estos pacientes; la principal 
variable independiente asociada fue la presencia de anemia. Cuando 
el ART se inició en primer lugar, la mediana hasta el comienzo del 
ATT fue 21,6 semanas; este tratamiento se inició durante los 3 
primeros meses en 56 pacientes (39%). Se observó un desenlace 
terapéutico desfavorable en 12% de estos pacientes y en 20% de los 
pacientes que iniciaron el ART en los primeros 3 meses. El riesgo de 
un desenlace desfavorable fue cuatro veces más alto en los pacientes 
con un recuento de linfocitos CD4 100 células/mm3.
Conclusión: La coordinación cronológica del ART y el ATT no 
representó un factor independiente de riesgo de obtener un 
desenlace desfavorable. Se recomienda la detección sistemática de la 
TB en los pacientes infectados por el VIH mediante pruebas 
diagnósticas rápidas y sensibles y una supervisión cuidadosa de la 
anemia y la inmunodepresión, con el objeto de obtener aun mejores 
desenlaces del ATT en los pacientes aquejados de coinfección 
TB-VIH.
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